Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Vaccine, Killed Virus, Killed Chlamydia

Verify with FDA CVM →

21 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
21
Total Reports
7
Deaths Reported
3330.0%
Death Rate

Active Ingredients

Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Vaccine, Killed Virus, Killed Chlamydia

Administration Routes

SubcutaneousOtherParenteralUnknown

Species Affected

Cat 21

Most Affected Breeds

Domestic Shorthair 17
Cat (unknown) 2
Domestic Mediumhair 2

Most Reported Reactions

Not eating 6
Lethargy (see also Central nervous system depression in 'Neurological') 5
Vomiting 5
Fever 4
Death 4
Diarrhoea 4
Limping 3
Lethargy (see also Central nervous system depression in Neurological) 3
Elevated blood urea nitrogen (BUN) 2
Death by euthanasia 2
Hiding 2
Hyperactivity 2

Outcome Breakdown

Recovered/Normal
6 (28.6%)
Died
5 (23.8%)
Ongoing
4 (19.0%)
Outcome Unknown
4 (19.0%)
Euthanized
2 (9.5%)

Data Summary

Metric Value
Total adverse event reports 21
Reports involving death 7
Case-fatality rate (reported events) 3330.0%
Distinct species in reports 1
Distinct breeds in reports 3
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Vaccine, Killed Virus, Killed Chlamydia Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 21 adverse event reports referencing Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Vaccine, Killed Virus, Killed Chlamydia, including 7 reports in which the animal died — a 3330.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Vaccine, Killed Virus, Killed Chlamydia. Reported administration routes include Subcutaneous, Other, Parenteral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Vaccine, Killed Virus, Killed Chlamydia reports are Cat (21 reports), with Cat accounting for the largest share. Within those species, Domestic Shorthair (17), Cat (unknown) (2), Domestic Mediumhair (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Vaccine, Killed Virus, Killed Chlamydia are Not eating (6), Lethargy (see also Central nervous system depression in 'Neurological') (5), Vomiting (5), Fever (4). Of the 21 reports with a coded outcome, Recovered/Normal is the leading category at 28.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Vaccine, Killed Virus, Killed Chlamydia.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial